Dapivirine Vaginal Ring Can Help Prevent HIV-1 Infection

This article originally appeared here.
Share this content:
Dapivirine Vaginal Ring Can Help Prevent HIV-1 Infection
Dapivirine Vaginal Ring Can Help Prevent HIV-1 Infection

THURSDAY, Dec. 1, 2016 (HealthDay News) -- Use of a vaginal ring containing dapivirine is efficacious for prevention of HIV-1 infection, according to a study published in the Dec. 1 issue of the New England Journal of Medicine.

Annalene Nel, M.B., Ch.B., Ph.D., from the International Partnership for Microbicides in Silver Spring, Md., and colleagues conducted a phase 3 trial involving 1,959 healthy, sexually active women, aged 18 to 45 years, from South Africa and Uganda. Participants were randomized in a 2:1 ratio to receive vaginal rings containing 25 mg dapivirine, which they inserted themselves every four weeks for up to 24 months, or placebo.

During follow-up, the researchers found that there were 4.1 seroconversions per 100 person-years in the dapivirine group, compared with 6.1 seroconversions per 100 person-years in the placebo group. The incidence of HIV-1 infection was significantly lower in the dapivirine versus the placebo group (hazard ratio, 0.69; P = 0.04). Among women aged older than 21 years and those aged 21 years or younger there were no significant differences in the efficacy of the dapivirine ring (P = 0.43 for treatment-by-age interaction). There were more serious adverse events in the dapivirine group than in the placebo group (2.9 versus 0.9 percent, respectively).

"Among women in sub-Saharan Africa, the dapivirine ring was not associated with any safety concerns and was associated with a rate of acquisition of HIV-1 infection that was lower than the rate with placebo," the authors write.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Artificial Intelligence Promising for CA, Retinopathy Diagnoses

Artificial Intelligence Promising for CA, Retinopathy Diagnoses

Two studies evaluate use; one for breast cancer, the other for diabetic retinopathy

USPSTF Recommends Against Hormone Tx Post Menopause

USPSTF Recommends Against Hormone Tx Post Menopause

Benefits do not outweigh harms of using hormone therapy for prevention of chronic conditions

Omalizumab Ups Efficacy of Multifood Oral Immunotherapy

Omalizumab Ups Efficacy of Multifood Oral Immunotherapy

Findings in multifood allergic pediatric patients

is free, fast, and customized just for you!

Already a member?

Sign In Now »